

Schrödinger Appoints Professor Brian Shoichet to Scientific Advisory Board

3/26/2019

NEW YORK – March 26, 2019 - Schrödinger today announced the appointment of Professor of Chemistry, Brian Shoichet, Ph.D., a widely published thought leader in the field of computational drug discovery, to its **scientific advisory board** (SAB). Schrödinger is a privately held company revolutionizing drug discovery and materials design through advanced molecular simulations.

“I am thrilled to join the exceptional team at Schrödinger in support of our shared mission to open new possibilities for drug discovery by continuing to advance the field of computational modeling,” said Professor Shoichet.

Professor Shoichet brings over two decades of extensive experience in drug discovery and design. He currently serves in the Department of Pharmaceutical Chemistry at the University of California, San Francisco, where his lab combines computational modeling with detailed experimental testing, and applies the resulting methods to new chemotype discovery. Professor Shoichet has published scores of papers in top scientific journals.

“We are delighted to welcome Brian to the advisory board,” said Ramy Farid, Ph.D., Schrödinger’s CEO. “We’re excited to collaborate with a leading scientist of Brian’s caliber to continue to expand our platform’s capabilities.”

“I am specifically interested in focusing on how FEP+ can improve workflows during early compound optimization for hits selected from large library docking screens,” Professor Shoichet added.

Professor Shoichet joins a team of leading biophysicists, chemists, and bioinformaticians on Schrödinger’s scientific advisory board, which is chaired by Professor Richard Friesner, director of the Columbia Center for Biomolecular Simulation and a co-founder of Schrödinger.

About Schrödinger

Schrödinger has a substantial and growing global business, licensing its industry-leading computational platform to pharmaceutical, biotechnology, chemical, and electronics companies to accelerate R&D in both drug discovery and materials design. Schrödinger has built a robust pipeline of therapeutic assets, held both internally and in partnerships, and has co-founded leading biotech companies, including Nimbus Therapeutics and Morpnic Therapeutic. Schrödinger's significant and ongoing investment in basic research continues to drive advances in its computational platform. Founded in 1990, Schrödinger has nearly 400 employees in its New York City headquarters and around the world. Visit [schrodinger.com](https://www.schrodinger.com) for more information.

Media Contact:

Stephanie Simon

stephanie@tenbridgecommunications.com

617-581-9333